In vitro models of the blood-brain barrier (BBB) are critical tools for the study of BBB transport and the development of drugs that can reach the CNS. Brain endothelial cells grown in culture are often used to model the BBB; however, it is challenging to maintain reproducible BBB properties and function. 'BBB organoids' are obtained following coculture of endothelial cells, pericytes and astrocytes under low-adhesion conditions. These organoids reproduce many features of the BBB, including the expression of tight junctions, molecular transporters and drug efflux pumps, and hence can be used to model drug transport across the BBB. This protocol provides a comprehensive description of the techniques required to culture and maintain BBB organoids. We also describe two separate detection approaches that can be used to analyze drug penetration into the organoids: confocal fluorescence microscopy and mass spectrometry imaging. Using our protocol, BBB organoids can be established within 2-3 d. An additional day is required to analyze drug permeability. The BBB organoid platform represents an accurate, versatile and cost-effective in vitro tool. It can easily be scaled to a highthroughput format, offering a tool for BBB modeling that could accelerate therapeutic discovery for the treatment of various neuropathologies.
Introduction
Diseases of the CNS represent a serious health burden 1, 2 . Their treatment is severely hampered by the BBB, a highly specialized arrangement of the vasculature that nature has evolved to regulate the entry of molecules into the brain and to provide protection from potentially harmful pathogens that enter the bloodstream. Unfortunately, the BBB also restricts the entry of the great majority of known therapeutics from the blood into the CNS 3 . However, the BBB does permit the passage of nutrients and other molecules necessary for CNS function; thus, it is permeable to some molecules. The ability to model, study and understand the BBB could lead to the identification of approaches that enable transport of pharmacological agents into the brain, which could substantially advance therapy for many neuropathologies.
The BBB is composed mainly of brain endothelial cells held closely together by tight junctions, and additional cell types with which the endothelial cells interact (including pericytes, microglial cells, neurons and astrocytic end-feet) 4, 5 . When cocultured under low-adherence conditions, human primary brain endothelial cells, astrocytes and pericytes assemble three-dimensional spheroidal structures composed of astrocytes in the core, with brain endothelial cells and pericytes encasing the exterior surface 6, 7 . We have previously demonstrated that these multicellular BBB organoids can be used as a reliable and predictive in vitro platform to analyze and screen for brain-penetrating compounds 6 . In this protocol, we describe how to establish BBB organoids and use them to assess whether compounds can cross the BBB.
The blood-brain barrier in vivo
Molecular entry through the BBB is strictly regulated in several ways.
• The tight junctions between endothelial cells prevent transcellular passage of molecules between the bloodstream and CNS tissues 8 .
• Specific molecular transporters shuttle essential molecules such as glucose and amino acids across the BBB 9,10 .
• Transcytosis, in which a specific receptor binds to its ligand in the circulation on the luminal (bloodfacing) side of the barrier and carries it to the abluminal (brain-facing) side, enables transfer of other specific ligands. Transferrin and low-density lipoprotein (LDL) are examples of ligands that bind their respective receptors and enter the brain via this mechanism 11 .
• Drug efflux pumps such as P-glycoprotein (Pg-P) provide an additional layer of regulation by actively excluding molecules from the brain 12 . Several approaches can be used to increase the permeability of the BBB. Physical approaches, such as osmotic shock using mannitol and focused ultrasound (FUS) non-selectively disrupt tight junctions transiently to allow unrestricted entry of vasculature components into the CNS 13, 14 . Other more selective strategies have been employed, such as the 'Trojan horse' approach, which exploits specific ligands as transport vehicles to hijack transcytosis receptors of the BBB. These include a 19-amino acid peptide called angiopep, which binds to the LRP-1 receptor 15 . Other promising approaches include the use of cell-penetrating peptides (CPPs) with the ability to readily cross membranes 16 . Such approaches could be used to tag drugs, antibodies and nanoparticles for CNS delivery. However, none of these strategies is broadly used clinically at present, and drug delivery across the BBB remains a formidable challenge. While neurosurgical procedures can be employed for direct intracranial injection of drugs into the brain, these methods are invasive and are associated with greater risk to the patient. The passage of drugs across the BBB is dependent on various factors, including molecular weight, hydrophobicity and polarity. Algorithms have been developed to help predict passage across the BBB, but these are not reliable, and drugs intended for clinical application need to be tested empirically 17 .
Modeling the BBB
In vitro models that can accurately mimic the BBB in culture are critical tools for the development of brain-permeable drugs at the preclinical level. Such models would facilitate the development of new and optimized approaches to the transport of drugs across the BBB, as well as improve the ability to predict which therapeutic compounds would cross the BBB. In vitro BBB modeling has been in development since the 1980s 18 , although reproducing key BBB properties ex vivo remains challenging. Many researchers have used the Transwell system to model the BBB. In the most commonly used Transwell system, brain endothelial cells are cultured within the apical (top) side of the Transwell insert, and astrocytes and pericytes are cocultured on the basal (bottom) side of the setup 19, 20 . More recently, the incorporation of endothelial cells from cord blood-derived hematopoietic stem cells or human induced pluripotent stem cells (hiPSCs) has also been explored 21, 22 . Although these platforms have proven useful for affinity-binding assays and the study of signaling, transmigratory processes and BBB-immune cell interactions 23 , these models are oversimplified and are associated with many well-known challenges 24 . For example, it has been documented that the endothelial monolayer cultured on the Transwell insert tends to exhibit various degrees of irregularity (multiple layers of endothelial cells or small holes in the monolayer in certain areas) that might confer leakiness and substantially affect the experimental results 24 . Microfluidic devices to simulate a more dynamic and realistic representation of the BBB by introducing blood flow to model the shear stress that occurs at the BBB have been developed to further improve physiological characteristics of the BBB in culture 25, 26 . A disadvantage of these systems is that specialized equipment and skillsets are required to build the platforms, hindering their broad application in the neuroscience community.
We recently introduced multicellular (containing human primary brain endothelial cells, astrocytes and pericytes) BBB organoids as a reliable and predictive in vitro analysis and screening platform for brain-penetrating compounds 6 . A key feature of our system is that all the cell types are in direct contact with one another (unlike in other previously established models), which has been demonstrated to be critical for the maintenance of BBB integrity 27 . We have shown that each organoid displays enhanced BBB characteristics (including increased tight junctions, adherens junctions and efflux pump expression) as compared with those of endothelial cells cultured in the Transwell system 6 . Importantly, the presence of additional barrier functions within the organoids, such as lack of paracellular permeability, high drug efflux activity and receptor-mediated transcytosis (via the LRP-1 receptor) have been demonstrated 6 . To our knowledge, the BBB organoids currently offer the highest-throughput BBB modeling platform available, owing to their miniature size and ease of culture. Hundreds of organoids can be used to simultaneously investigate numerous therapeutic compounds, and the throughput can be further enhanced through automated robotics-assisted detection techniques. We used these organoids to develop various new BBB-penetrating peptides and confirmed their permeability in vivo 6, 28 . Organoid growth does not require external scaffold material. Although our approach does not incorporate flow (such as that incorporated in a microfluidic chamber), shear stress is introduced into the platform through constant rotation of the organoids at a regulated speed while the organoids are incubated with the test compound(s).
This protocol provides a detailed description of how to culture, maintain and employ the BBB organoids for investigating the BBB permeability of a given compound. However, although this platform is useful for rapid and predictive screening of drug permeability across the BBB, findings obtained using this in vitro tool should also be complemented with in vivo studies.
Experimental design
Brain endothelial cells, pericytes and astrocytes are cultured together in low-adherence conditions in a 1:1:1 ratio and allowed to self-assemble into multicellular spheroids over a 24-48-h period. The quality of established organoids should be assessed under a microscope before use. Organoids that have formed properly can be pooled together in working culture medium and then incubated with the test compound of interest. We have incubated organoids for differing lengths of time (1-24 h). The concentration and period of incubation must be optimized for a given drug (it is also advisable to include proper positive and negative controls in all experiments). After incubation, the organoids are washed thoroughly and processed to enable evaluation of compound permeability. We describe how to assess permeability using two different detection strategies: confocal microscopy, for fluorescently labeled compounds, and MALDI mass spectrometry imaging (MSI), for nonfluorescent small molecules. Typically, the utility of one type of detection method is sufficient for a given compound, although both methods can be used to provide additional verification of a result if necessary. Confocal microscopy tends to be the preferred methodology, as it offers advantages such as better detection sensitivity, higher throughput and fewer tissue preparation steps, as compared with mass spectrometry. Furthermore, the fluorescence detection route allows researchers to co-incubate their compound of interest with fluorescent dextran as an internal negative control to assess the integrity of the BBB organoids. However, as most drugs are not inherently fluorescent, the use of MSI for detection might be the only option. In the 'Anticipated results' section, we show the results obtained following the analysis of angiopep-2 and BKM-120 (known BBB-permeable compounds) 29, 30 to demonstrate typical results obtained when using this protocol. When considering the study of toxic drugs using this platform, the preservation of organoid integrity and function should be investigated by analyzing the ability of the organoids to exclude dextran in the presence of the drug. • Trifluoroacetic acid (TFA; Sigma-Aldrich, cat. no. T6508) ! CAUTION TFA is harmful if swallowed, inhaled or absorbed through the skin. Wash the skin thoroughly after handling and use only in wellventilated areas.
Materials
• Triton X-100 (Sigma-Aldrich, cat. no. T8532) ! CAUTION Triton X-100 is harmful if swallowed. It causes skin and eye irritation. • BKM-120 (Selleckchem, cat. no. S2247) ! CAUTION BKM-120 can be harmful if swallowed, inhaled or absorbed through the skin.
• Dabrafenib (Selleckchem, cat. no. S2807)
• Peptides of interest. The example results shown in this paper were obtained following the exposure of BBB organoids to angiopep-2 (TFFYGGSRGKRNNFKTEEY) and a corresponding scramble control peptide (GNYTSRFEREYGKFNKFGT). These peptides were synthesized and purified in the Pentelute laboratory (Department of Chemistry, Massachusetts Institute of Technology). These peptides were labeled with tetramethylrhodamine (TAMRA) as described in Box 1.
• Kollisolv PEG 300 (Sigma-Aldrich, cat. no. 91462-1KG)
Reagent setup
1% (wt/vol) Agarose Dissolve 0.5 g of agarose in 50 mL of Milli-Q water or PBS. Heat until the agarose is completely dissolved. Prepare fresh agarose for each new experiment.
Wash buffer for MSI Dissolve 0.12 g of ammonium acetate in 200 mL of HPLC-grade water, pH 7. Store the bottle at 25°C or in the refrigerator for no longer than 6 months.
Box 1 | TAMRA-labeled angiopep-2
Given that the goal is to verify active transport across the BBB, the exact choices of fluorophore and linker are not critical to the success of the experiment. However, for the experiments in Fig. 4 , the fluorophore was 5-TAMRA, and the linker was an amide to the N terminus. Multiple options exist for obtaining fluorophore-labeled peptides to validate the properties of the BBB organoids. 5-TAMRA-labeled peptides can be ordered from a commercial vendor or a core facility. From N to C terminus, the peptide sequence of TAMRA-angiopep-2 is TAMRA-TFFYGGSRGKRNNFKTEEY. The control-scrambled angiopep sequence is TAMRA-GNYTSRFEREYGKFNKFGT. If the user has experience with solid-phase peptide synthesis, the peptides can be prepared through standard solid-phase peptide synthesis using Fmoc chemistry. For the experiments in Fig. 5 , the peptides were prepared by automated flow peptide synthesis 34 , and 5-TAMRA carboxylic acid was coupled to the N terminus of the resinbound peptide using standard active ester chemistry. After cleavage, the peptides were purified by reverse-phase HPLC. The purity and identity of the final dye-labeled peptides were confirmed by liquid chromatography mass spectrometry.
2,5-Dihydroxybenzoic acid matrix (MALDI matrix)
Dissolve 800 mg of 2,5-DHB (160 mg/mL) in 5 mL of 70:30 methanol/H 2 O and 0.1% (vol/vol) TFA. Prepare fresh solution for each new experiment.
Endothelial growth medium (EGM-2) (for immortalized hCMEC/D3)
Add all supplements and growth factors provided by the manufacturer (hEGF, hydrocortisone, GA-100, FBS, VEGF, hFGF-B, R³-IGF-1, ascorbic acid and heparin) to 500 mL of EBM in a sterile tissue culture hood. Invert the bottle a few times to ensure thorough mixing of all components. Store the bottle at 2-8°C in the refrigerator for no longer than 6 weeks.
ECM (for primary HBMECs)
Add 25 mL of FBS and 5 mL of ECGS to 500 mL of EBM. Invert the bottle a few times to ensure thorough mixing of all components. Store the bottle at 2-8°C in the refrigerator for no longer than 6 weeks.
Astrocyte growth medium (AGM-2)
Add all supplements and growth factors provided by the manufacturer (rhEGF, insulin, ascorbic acid, GA-100, L-glutamine and FBS) to 500 mL of astrocyte growth medium in a sterile tissue culture hood. Invert the bottle a few times to ensure thorough mixing of all components. Store the bottle at 2-8°C in the refrigerator for no longer than 6 weeks.
Pericyte medium Add 10 mL of FBS and 5 mL of PGS to 500 mL of pericyte basal medium in a sterile tissue culture hood. Invert the bottle a few times to ensure thorough mixing of all components. Store the bottle at 2-8°C in the refrigerator for no longer than 6 weeks.
BBB working medium
For organoid formation using hCMEC/D3 cells, add endothelial growth supplements hEGF, hydrocortisone, GA-100, hFGF-B, R³-IGF-1, ascorbic acid and heparin to 500 mL of EBM (from Lonza) in a sterile tissue culture hood. Supplement this medium with 2% (vol/vol) human serum. Invert the bottle a few times to ensure thorough mixing of all components. Store the bottle at 2-8°C in the refrigerator for no longer than 6 weeks. c CRITICAL Do not add FBS (as the medium has already been supplemented with human serum) or VEGF (as VEGF will disrupt the tight junctions on the organoid surface) to this medium. c CRITICAL For organoid formation using primary HBMECs, add 2% (vol/vol) human serum to EBM (from ScienCell) and exclude supplementation with FBS and ECGS. HBMECs in ECM. Maintain primary HBVPs in pericyte medium and primary human astrocytes in astrocyte growth medium (AGM-2). Culture each of these cell types in~20 mL of cell culture medium in a T75 cell culture flask or in~30 mL of cell culture medium in a T175 cell culture flask (Cell+ growth surface for sensitive adherent cells) with a yellow vented cap in a humidified incubator at 37°C with 5% CO 2 and 95% natural air. Culture the cells for a few days until they reach a confluency of~80% (see bright-field images in Fig. 1 ) in the appropriate cell culture medium. c CRITICAL STEP For experimental use, maintain astrocytes between passages 2 and 5, HBVPs between passages 2 and 10, and HBMECs between passages 2 and 5. If required, passage the cells by trypsinization when they reach 80% confluency (as described in Steps 8-11) and split at a 1:10 ratio for each cell type. Upon obtaining a new stock, or as the cell passage reaches its higher limit, confirm the identity of each cell type by immunofluorescence staining of its cell-specific marker(s) (a marker for astrocytes is GFAP; a marker for HBVPs is NG2 and markers for endothelial cells are CD31 and VE-cadherin) (Fig. 1) . Cell identity and authentication can also be confirmed by transmission electron microscopy 6 . ? TROUBLESHOOTING 2 Pre-warm the appropriate BBB working medium, D-PBS, EGM-2 (or ECM), AGM-2, pericyte medium and 0.05% (vol/vol) trypsin-EDTA in a clean water bath at 37°C for~30 min.
Preparation of low-adhesion agarose plate • Timing 25-35 min 3 Prepare 1% (wt/vol) agarose by mixing 0.5 g of molecular biology-grade agarose in 50 mL of Milli-Q water or D-PBS in a conical flask. 4 Microwave the mixture for 1-2 min (with pauses between to prevent boiling over) until the agarose is completely dissolved. 5 Transfer the flask containing the melted agarose to a sterile tissue culture hood and pour the solution into a 50-mL pipette basin. 6 Pipette 50 μL of agarose into each well of a 96-well plate while it is still hot, using sterile pipette tips and a multichannel pipette. c CRITICAL STEP Work quickly at this step to avoid cooling/solidification of the agarose solution during pipetting, as this can lead to uneven agarose coating within each well. 7 Set the plate aside to cool at room temperature (20-24°C) and allow the agarose to solidify for 15 min. ? TROUBLESHOOTING j PAUSE POINT If the plate is not used immediately, add~50 μm of BBB working medium to each well to prevent the agarose from drying, and store the plate at 4°C for up to 3 h. 10 Add 1-1.5 mL of 0.05% (vol/vol) trypsin-EDTA to each flask, and gently rock each flask back and forth to ensure that the trypsin solution is properly distributed over all the cells on the surface of the flask. Place the flasks back into the 37°C incubator for 2-5 min or until the cells begin to detach from the surface of the flask. If necessary, tap the dish to help release the cells. 11 Add 9 mL of BBB working medium to each flask to resuspend the cells, generating a working stock for each cell type. 12 Count each cell type using a hemocytometer and determine the concentration of each working stock.
Organoid culture • Timing 48 h 13 Calculate the volume needed to seed 1.5 × 10³ hCMEC/D3 cells (or HBMECs), HBVPs and astrocytes. To achieve a volume of 200 μL per well in a 96-well agarose plate, subtract the total cell volume from 200 μL, and pipette that amount of BBB working medium into each well, using a multichannel pipette. Then, using a multichannel pipette add the appropriate volume of each cell type to each well containing the BBB working medium. The final volume in each well should be 200 μL. c CRITICAL STEP To ensure proper cell seeding, assess each well under an inverted light microscope after each seeding step. To reduce the 'edge effect' in a 96-well plate, where the level of evaporation at the edge wells is much higher, fill the outer-edge wells with 200 μL of either D-PBS or BBB working medium to act as a moisture barrier, and use only the inner wells of the plate for culturing the BBB organoids. ? TROUBLESHOOTING 14 Incubate the plate at 37°C in a humidified CO 2 incubator for 48 h. The organoids should assemble properly into compact spheroids within 12-24 h (Fig. 2a) . After 48 h, assess the organoid quality in each well before collecting them for experimental purposes (see Fig. 2b as a general guideline) . Proceed to the next step only with organoids that have assembled properly. Collect each acceptable organoid by pipetting, and pool them together in a microcentrifuge tube for experimental use (Fig. 2c) . c CRITICAL STEP Organoid quality can be further assessed by immunostaining example organoids for expression of markers of the BBB, such as tight junctions (ZO-1) and efflux pumps (Pg-P) as illustrated in Fig. 2d ,e.
Analysis of BBB-penetrating compounds • Timing between 1-24 h 15 Either pool multiple organoids together in microcentrifuge tubes in BBB working medium for subsequent confocal fluorescence microscopy (option A) or MALDI MSI (option B) or treat a single organoid separately with a test compound for confocal fluorescence microscopy (option C). When choosing which method to use, bear in mind that confocal fluorescence microscopy can be done only if the compound of interest is inherently fluorescent or is labeled with a fluorophore. For nonfluorescent molecules, MALDI MSI is an appropriate alternative. The use of multiple organoids pooled together (shown in Fig. 2b ) allows them to be used simultaneously to test a given compound. The use of pooled organoids is best for short-span experiments, when organoids are incubated with the test compound for only a few hours. For experiments in which long-term incubation (over days) is needed, a single organoid can be treated separately with a test compound while in culture in a 96-well plate (option C). Although this method is slightly more laborious and utilizes a higher amount of test reagent, this is necessary to prevent the organoids from merging/ clumping together in a pooled environment over time. In addition, the test compound can be coincubated with fluorescent high-molecular-weight dextran as an internal control to ensure that the compound of interest does not disrupt the surface barrier of the organoid. If a high level of the test compound is detected within a functional organoid that can exclude dextran, this would suggest true BBB permeability.
(A) Treatment of pooled organoids for confocal fluorescence microscopy (i) Use a 200-μL pipette tip to pool seven to ten organoids per group into a 0.6-mL microcentrifuge tube in BBB working medium by transferring single organoids from the agarose-coated 96-well plate. (ii) Gently spin down the organoids using a tabletop minicentrifuge for 2-3 s (at~100-300g at 25°C), and aspirate the medium carefully without disturbing the organoids. Add 500 μL of fresh BBB working medium to the tube. (iii) Pipette the (fluorescently labeled) test compound into each tube containing organoids to a desired final concentration (typical range is 1-20 μM) and mix well by inverting the tube. If desired, also add a fluorescently labeled high-molecular-weight dextran to a final concentration of 10 μg/mL as an internal control. ? TROUBLESHOOTING (iv) Incubate the organoids for the desired duration (typically between 1 and 24 h) under constant rotation in a 37°C incubator. c CRITICAL STEP It is necessary to test a diverse range of working concentrations and incubation periods for each test compound to determine the optimal parameters for analyzing BBB permeability without disrupting the structure/function of the organoids. This can be examined by co-incubation of the test compound with dextran (as described above). This step is particularly important if the test compound is known to be toxic to cells (e.g., anticancer drugs). Table 1 provides a list of peptides that have been previously tested for BBB permeability using the organoid model. ? TROUBLESHOOTING (v) Gently spin the organoids down using a minicentrifuge for 2-3 s (~100-300g at 25°C) and carefully aspirate the solution. Add 500 μL of BBB working medium or D-PBS to wash the organoids/remove any excess test compound. Repeat the washing step at least 3× by centrifuging and washing the organoids in working medium or D-PBS each time. (B) Treatment of pooled organoids for MALDI MSI (i) Use a micropipette to collect/pool 150-200 organoids per group into a 1.5-mL microcentrifuge tube in BBB working medium. c CRITICAL STEP Organoid cryosections are analyzed to examine whether a test compound has penetrated the surface barrier and entered the core. This requires a sizable pellet of pooled organoids for each test group to ease the cryosectioning process (see below).
(ii) Gently spin the organoids down for 2-3 s (at~100-300g at 25°C) and aspirate the medium carefully. Add 1 mL of fresh BBB working medium to the tube. (iii) Add the test compound (of known molecular weight) to the tube to the desired final concentration (typical range is 1-10 μM) and mix well by inverting the tube. c CRITICAL STEP As described for option A, determine if the desired concentration of the test compound would disrupt the integrity of the BBB surface barrier by co-incubation with a high-molecular-weight dextran. ? TROUBLESHOOTING (iv) Incubate the organoids at 37°C in an incubator under constant rotation. The incubation period is typically between 1 and 24 h, though this parameter should be optimized for each compound.
? TROUBLESHOOTING (v) Gently spin the organoids down, using a mini centrifuge for 2-3 s (~100-300g at 25°C), and carefully aspirate the solution. Add 500 μL of wash buffer for MSI (7.5 mM ammonium acetate) to wash the organoids/remove any excess test compound. Repeat this washing step 5×. (C) Treatment of individual organoids in a 96-well plate (i) Set up a 96-well plate containing one organoid per well. Pipette the test compound into each well containing a single organoid at a desired concentration. Pipette up and down gently to ensure proper mixing. ? TROUBLESHOOTING (ii) Incubate the plate in a humidified CO 2 incubator at 37°C (typical duration is 1-3 d).
Change the working medium every 2 d if a longer incubation period is required. (iii) Use a micropipette to collect the organoids into a 0.6-mL microcentrifuge tube. Organoids from the same test group can be pooled together in the same tube. (iv) Gently spin the organoids down, using a minicentrifuge for 2-3 s (~100-300g at 25°C), and carefully aspirate the solution. Add 500 μL of BBB working medium or D-PBS to wash the organoids and to remove any excess test compound. Repeat this washing step at least 3× by centrifuging and washing the organoids in working medium or D-PBS each time. z-stack images, starting from the outermost surface of the organoid toward the core, using a 20× objective (up to~100-μm deep, or until the fluorescence level has degraded). If a two-or multiphoton microscope is used, a greater imaging depth (>100 μm) can be achieved. c CRITICAL STEP For quantitative analysis, it is important to adjust the microscope settings (laser power, exposure time and/or gain) appropriately so that the signal intensity of the test compound at the desired depth of the organoid will fit within the dynamic range of the detector. Settings that are too low (below the detectable threshold) will not display any fluorescence, whereas settings that are too high will result in saturated pixels that are not quantifiable. (B) Imaging using MALDI MSI (i) Start the process of chilling the cryostat chamber and specimen holder to~−26°C so that these are at the appropriate temperature and ready for Step 16B(v). (ii) Coat the pipette tip with D-PBS containing 0.1-0.2% (vol/vol) Triton-X by pipetting up and down a few times (for~5 s), and transfer the organoids to a 0.2-mL PCR tube in 200 μL of ammonium acetate buffer. c CRITICAL STEP During the transfer process, organoids can stick to the inner wall of the pipette tip, causing them to be irretrievable for further analysis. To prevent this, coat the inner wall of the pipette tip with 0.1-0.2% (vol/vol) Triton-X in D-PBS solution prior to transferring the organoids. ? TROUBLESHOOTING (iii) Gently spin the organoids down for 2-3 s at~100-300g at 25°C to pool them at the bottom of the PCR tube. (iv) Flash-freeze the organoids by placing the tube in a dry ice/ethanol bath for a few minutes until the buffer solution is completely frozen. (v) Mount the top of the frozen tube onto a sample disk/holder using the Tissue-Tek OCT medium and place the setup on dry ice until the OCT medium is frozen (Fig. 3a) . Then, clamp the sample disk containing the frozen tube of organoids to the sample stage of the cryostat (Fig. 3a) , with both the chamber and specimen holder chilled at~−26°C. (vi) Cryo-section the bottom of the frozen tube containing the organoids into 12-μm slices, and thaw-mount the organoid tissue on an ITO-coated microscopic slide for MALDI MSI. Also, mount serial sections on a regular positively charged glass slide for hematoxylin and eosin (H&E) staining to verify the quality of the tissue sections. c CRITICAL STEP To ensure that the sections are mounted on the correct side of the ITOcoated slides, measure the resistance on both sides of the slide, using a voltage meter. ITO coating causes electrical resistance, whereas the uncoated side is not conductive (Fig. 3b) . Ensure that sections are mounted on the ITO-coated side. (xi) Acquire mass spectra using an FTICR mass spectrometer. Set the pixel step size for the surface raster to a maximum of 30 μm. Analyze the compound, using a positive ion mode targeting the molecule of interest with continuous accumulation of selected ions (CASI) in the corresponding mass range (Fig. 3c) .
Data analysis • Timing 1-2 h
17 Analyze compound permeability using option A if you have carried out confocal fluorescence microscopy and option B if you have carried out MALDI MSI.
(A) Quantification of z-stack images from confocal fluorescence microscopy c CRITICAL Quantification of acquired z-stack images can be performed by measuring the mean fluorescence intensity of the compound inside the organoid at a depth between~50 and 100 μm using ImageJ (Fig. 4) . 
Troubleshooting
Troubleshooting advice can be found in Table 2 . 
Anticipated results
Investigation of active transport across the BBB organoid surface via confocal microscopy BBB organoids established using hCMEC/D3 cells, pericytes and astrocytes should express cellspecific markers. Expression of these markers can be determined by immunofluorescence staining (Fig. 1) . The example results we show here demonstrate that angiopep-2-a peptide ligand of the lowdensity lipoprotein (LDL) receptor-related protein-1 (LRP-1) receptor, which is known to cross the BBB via receptor-mediated transcytosis 15, 29 -penetrates the BBB organoids. For detection by confocal microscopy, angiopep-2 and a corresponding scramble control peptide were labeled with a TAMRA dye (Box 1). After incubation with the organoids, z-stack confocal fluorescence images were acquired to capture the level of accumulation of each compound within the organoid core. Permeability is quantified by measuring the total mean fluorescence signal intensity of the optical sections at a depth Statistical analysis was performed using one-way ANOVA and Tukey's multiple comparison test. The graph depicts the sum of the mean fluorescence intensity of the core area from optical sections at a depth of 56-96 µm with standard deviation bars (****P < 0.0001; ***P < 0.001; n organoids = 5). d, Graph depicting the transport of Bip(1) in a concentration-dependent manner after 2 h of incubation (n spheroid = 5-7). e, Time-course analysis of the transport of Cy5-Bip(1) into the BBB organoid over 26 h (at a 10 μM concentration) (n spheroid = 4-6). The graphs display mean Cy5.5 fluorescence intensity, quantified at an 88-μm depth from the surface of each spheroid, with standard deviation bars. Scale bars, 100 µm. NS, not significant (P > 0.05).
between 56 and 96 μm. As expected, we observed a high influx of angiopep-2 into the organoids as compared with the scramble control peptide, whereas rhodamine-dextran and unconjugated rhodamine dye were undetectable (Fig. 5a-c) . We also demonstrated the permeability of Bip(1), a CPP that can penetrate the BBB organoids in a time-and concentration-dependent manner (Fig. 5d ,e) 6 .
Analysis of small-molecule drug transport using MALDI MSI MALDI MSI can be used to analyze whether nonfluorescent molecules penetrate the BBB organoids.
In our example results, we show data following incubation with phosphatidylinositol 3-kinase inhibitor BKM120, a molecule known to cross the BBB 30, 31 , and dabrafenib, an inhibitor of the serine/ threonine-protein kinase B-Raf with limited BBB penetration 32 . Established organoids were incubated with 10 μM of either drug for 24 h, and then cryosectioned for MS imaging. The tissue sections of the organoids were scanned, and MS data were acquired at a spatial resolution of 30 μm to allow evaluation of drug penetration inside the organoids. A high level of BKM120 was seen in the BBB organoids, as would be expected given that BKM120 can penetrate the BBB, whereas dabrafenib was not detected (Fig. 3c) .
Conclusion
The BBB organoid platform models the BBB in vitro, recapitulating key BBB properties and functions. This high-throughput and cost-effective approach can offer a paradigm shift for in vitro BBB modeling and investigation of brain-permeable molecules for a broad range of therapeutic application for CNS diseases.
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